Global Viral Inactivation Market Analysis 2016 to 2026 - Market Expected to Reach $1,209.17 Million by 2026 - ResearchAndMarkets.com
Global Viral Inactivation Market Analysis 2016 to 2026 - Market Expected to Reach $1,209.17 Million by 2026 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Global Viral Inactivation Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.
The Viral Inactivation market is expected to reach $1,209.17 million by 2026 growing at a CAGR of 14.2% from 2018 to 2026.
Factors such as increasing government support for pharmaceutical and biotechnology industries, an increase in the number of drug launches & approvals and rising investment in the life sciences sector are driving the market growth. Though, high cost of biologics and biosimilar products development & manufacturing restrain the market growth.
Based on the product, Kits and reagents are expected to have a lucrative growth during the forecast period due to their continuous usage by pharmaceutical and biopharmaceutical companies. With an increase in the number of pharmaceutical and biopharmaceutical companies and the rise in R&D spending for the purpose of new drug development, the usage of kits and reagents has increased tremendously.
Key Questions Answered in this Report:
- How this market evolved since the year 2016
- Market size estimations, forecasts and CAGR for all the segments presented in the scope
- Key Market Developments and financials of the key players
- Opportunity Analysis for the new entrants
- SWOT Analysis of the key players
-
Fastest growing markets analysed during the forecast period
The key vendors mentioned are Merck KGAA, Cerus Corporation, Thermo Fisher Scientific Inc., Sartorius AG, Danaher Corporation, Texcell, Inc., Parker Hannifin Corporation, Sanofi SA, SGS SA, Invitrogen Corp., General Electric Co., Rad Source Technologies, Qiagen NV, ZeptoMetrix Corp., MockV Solutions, Vironova AB, Viral Inactivated Plasma Systems SA, and BioReliance.
Key Questions Answered in this Report:
- How this market evolved since the year 2016
- Market size estimations, forecasts and CAGR for all the segments presented in the scope
- Key Market Developments and financials of the key players
- Opportunity Analysis for the new entrants
- SWOT Analysis of the key players
-
Fastest growing markets analysed during the forecast period
Key Topics Covered:
1 Market Synopsis
2 Research Outline
2.1 Research Snapshot
2.2 Research Methodology
2.3 Research Sources
2.3.1 Primary Research Sources
2.3.2 Secondary Research Sources
3 Market Dynamics
3.1 Drivers
3.2 Restraints
4 Market Environment
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Viral Inactivation Market, By Product
5.1 Introduction
5.2 Services
5.3 Viral Inactivation Systems and Accessories
5.4 Kits and Reagents
6 Global Viral Inactivation Market, By Method
6.1 Introduction
6.2 Pasteurization
6.3 Solvent Detergent Method
6.4 Other Methods
7 Global Viral Inactivation Market, By Application
7.1 Introduction
7.2 Blood and Blood Products
7.3 Tissues and Tissue Products
7.4 Vaccines and Therapeutics
7.5 Stem Cell Products
7.6 Cellular and Gene Therapy Products
8 Global Viral Inactivation Market, By End User
8.1 Introduction
8.2 Pharmaceutical and Biotechnology Companies
8.3 Academic Research Institutes
8.4 Contract Research Organizations
8.5 Blood Banks and Hospitals
9 Global Viral Inactivation Market, By Geography
9.1 Introduction
9.2 North America
9.3 Europe
9.4 Asia Pacific
9.5 South America
9.6 Middle East & Africa
10 Strategic Benchmarking
11 Vendors Landscape
11.1 Merck KGAA
11.2 Cerus Corporation
11.3 Thermo Fisher Scientific Inc.
11.4 Sartorius AG
11.5 Danaher Corporation
11.6 Texcell, Inc.
11.7 Parker Hannifin Corporation
11.8 Sanofi SA
11.9 SGS SA
11.10 Invitrogen Corp.
11.11 General Electric Co.
11.12 Rad Source Technologies
11.13 Qiagen NV
11.14 ZeptoMetrix Corp.
11.15 MockV Solutions
11.16 Vironova AB
11.17 Viral Inactivated Plasma Systems SA
11.18 BioReliance
For more information about this report visit https://www.researchandmarkets.com/r/m0wcqb
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
